精準醫療市場-各國電子醫療（e-Health）促銷政策的推進（2018-2025）

National eHealth Initiatives Advancing Global Precision Medicine Market, 2018-2025

出版日期: 2020年07月28日 | 出版商:

Frost & Sullivan | 英文 66 Pages | 商品交期: 最快1-2個工作天內

價格

全貌
簡介
目錄

簡介

來自保險公司的巨大壓力和放寬管制將藥品業務從規範模型轉變為預測/個性化模型，這正在將精密醫學轉變為廣泛接受的產品。伴隨診斷（CDx）和靶向療法（TRx）將用於癌症治療以外的其他領域（傳染病，中樞神經系統（CNS），心血管疾病等），而全組學技術將用作目標分子。它也用於識別。另一方面，電子醫療（e-health）在世界主要國家-愛沙尼亞，芬蘭，加拿大，中國，澳大利亞，台灣，韓國，新加坡，日本等方面取得了重大進展，基礎設施發展和技術進步也正在以大筆投資進行。它被用於包括精密醫學在內的各種醫學領域。

本報告分析了全球精密醫學（PM）市場的結構/趨勢和增長機會，並分析了生態系統的組成部分，當前技術水平和未來技術進步機會以及整體市場規模。趨勢展望，按領域劃分的詳細趨勢，主要的市場促進和製約因素，以及行業利益相關者在未來以及主要國家的當前/未來響應狀態中要解決的問題，尤其是電子醫療（e-health）我們將收集並提供與系統有關的信息。

精準醫學的核心領域:基於情景的預測
精密醫學的核心領域:預測樂觀情景的前提
精密醫學的核心領域:預測的前提-悲觀情景
精準醫學的核心領域:市場利潤情景預測分析
精密醫學的核心領域:按細分細分的市場利潤預測
精密醫學的核心領域:主要細分領域的預測假設

精密藥品集群:主要國家的比較分析

主要國家與精密醫學的關係
各國精確醫療對策:需要考慮的因素
精準醫療反應指數:美國
精準藥物反應指數:歐盟國家/英國
精準藥物反應指數:亞太地區

精準醫學的增長機會

主要增長機會

機會分析，伴隨診斷（CDx）和基於生物標記物的靶向治療（TRx）

增長機會（1）:CDx和基於生物標記的TRx
精準醫學臨床試驗趨勢:主要地區
伴侶生物標誌物調查的主要領域
精準醫學時代的新臨床試驗設計
主要國家的TRx/CDx合規指數

機會分析-基因組學技術進行精確診斷

增長機會（2）:用於精確診斷的基因組學技術
精密醫學的患者分層:通過組學/診斷因素
主要新技術和方法的採用水平
用於精確診斷的基因組學技術
主要NGS供應商的狀態
主要國家的組學研究響應指數

機會分析-精準醫學信息學

增長機會（3）:精準醫學的信息學解決方案
精準醫學信息學:市場形勢
精準醫學信息學:市場規模
推薦行為（C2A）:用於Xifin-MDx的精確醫學信息學（分子診斷）
主要國家/地區的電子醫療（電子醫療）合規性指數

主要結論

附錄

Product Code: K3BE-52

Taiwan, Estonia, and Finland Emerging as Key Markets Fueling Growth Opportunities in Precision Medicine Informatics

Precision medicine is transitioning toward wider acceptance, due to mounting payer pressures and regulatory changes that are shifting pharma businesses from prescriptive to more predictive and personalized models. Emergence of value-based reimbursement models and healthcare consumerism trends are helping move the treatment model from 'one-size-fits-all' to a stratified and outcome-based targeted therapeutics concept called 'precision medicine' (PM).

Companion diagnostics (CDx) and targeted therapeutics (TRx) are going beyond oncology and spreading more toward therapeutic areas such as infectious diseases, central nervous system (CNS), and cardiovascular diseases. Despite a relatively high success rate for PM R&D assets commercialization in recent years, considerable challenges exist around proving clinical utility and a regulatory and reimbursement framework, which is rigid, decentralized, and non-uniform.

Advances in omics technologies help in identifying molecular targets with the help of molecular insights generated by datasets about the disease pathogenesis. PM informatics is the key component of the PM ecosystem. PM-cognitive analytic platforms capable of leveraging genomic, clinical, financial, and lifestyle data, while delivering actionable clinical insights at the point of care, are gaining market traction. Big Data and Artificial Intelligence (AI) are the key enablers for utilizing the full potential of PM for building predictive models based on multi-omics data, given a big hurdle in the adoption of PM is lack of technology infrastructure.

Genomic sequencing has huge potential to support the COVID-19 outbreak exploration, especially in comprehending the re-emergence of potential COVID-19 outbreaks.

In terms of geographic outlook, although the specific focus on PM research started in the United States and the EU, countries such as Canada, China, Australia, Taiwan, South Korea, Singapore, and Japan have made significant advances in recent years in this area by way of significant investments to develop in-country research and scientific expertise to improve access. Considering the infrastructure requirements for utilizing omics in clinical practice, China and Japan are beating other leading countries in terms of both research initiatives and regulations and infrastructure development.

Research Scope:

This research service analyzes the key building blocks for the precision medicine ecosystem to provide strategic imperatives and growth opportunities for key participants. The study captures both the global and regional flavors for PM market opportunity realization such as: market projections, drivers and restraints, country readiness index, and major government and commercial initiatives. The study also provides live case studies and innovative business models for leading companies in the PM space.

Key Issues Addressed:

What does the PM ecosystem look like? Who are the key stakeholders and what are their roles?

What are the gaps in the PM ecosystem and how these can be filled by market partners?

How big is the PM market? What are the growth opportunities by major therapeutic areas, market segments, and technologies by 2025?

What are the major market drivers and restraints for the PM market?

Which are the countries that demonstrate the highest growth opportunities for PM? How are the regulatory and reimbursement landscape evolving across these countries?